Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD7-CAR T Cells in High-risk Acute T-cell Leukemia / Lymphoma
NCT04840875Phase 1Completed
- Sponsor
- Beijing Boren Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous CD7-CAR T cells in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Beijing Boren Hospital. Primary endpoint: Dose-Limiting Toxicity rate at 21 days. Started Sep 2021; status: completed.
02
Drugs
autologous CD7-CAR T cells
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT04840875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840875.